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Role of prostaglandins and angiotensin H in experimental glomerulo.
nephritis. Moderate autologous nephrotoxic serum nephritis (NSN) in
rats causes no reduction in GFR despite a reduction in ultrafiltration
coefficient (K1) to less than one-half of normal. An increase in
intraglomerular hydraulic pressure maintains GFR, but the signal and
efferent mechanisms for this adaptation remain unknown. Indometh-
acm and saralasin were used to study the possible roles of prostaglan-
dins and angiotensin II (A-lI) in the adaptation to NSN. Indomethacin
decreased renal blood flow (RBF) in NSN (— 8.6%, P < 0.001), but not
in controls. Renal vascular resistance (RVR) increased in NSN (+
9.6%, P < 0.01), but decreased in controls (— 5.6%, P < 0.01). GFR
decreased in NSN (— 22.3%, P < 0.01), but increased in controls (+
10.3%, P < 0.001). Urinary POE2 excretion decreased markedly both in
NSN and controls. With combined treatment using indomethacin and
saralasin, RBF increased in NSN (+ 22.4%, P < 0.001), but did not
change in controls. RVR decreased in NSN (— 21.5%, P < 0.001), but
was unchanged in controls. GFR remained unchanged both in NSN and
controls. With saralasin alone, RBF increased both in NSN (+ 21.4%,
P < 0.001) and in controls (+ 14.4%, P < 0.001). RVR decreased both
in NSN (— 21.8%, P < 0.001) and controls (— 18.7% P < 0.001). GFR
increased (+ 12.3%, P < 0.05) in NSN, but did not change in controls.
Urinary POE2 excretion was increased in NSN compared to controls,
decreased markedly in NSN after either indomethacin or saralasin
infusion. These findings indicate an increased action of angiotensin II in
NSN, and, in addition, provide evidence for increased action of
vasodilator prostaglandins, perhaps secondary to enhanced angiotensin
II action. These results point to an enhanced intrarenal action of
angiotensin II in NSN.
Role des prostaglandines et de l'angiotensine II lors d'une glomérulo-
néphrite experimentale. Une nCphrite sCrique nephrotoxique (NSN)
autologue moddrde chez des rats n'entrafne pas de reduction du debit de
filtration glomCrulaire (GFR) malgré une baisse du coefficient
d'ultrafiltration (K1) a moms de Ia moitié de Ia normale. Une augmen-
tation de Ia pression hydraulique intraglomerulaire maintient GFR, mais
le signal et Ia mécanisme nCcessaires a cette adaptation restent incon-
nus. Dc l'indomCthacine et de Ia saralasine ont été employees pour
Ctudier les rOles possibles des prostaglandines et de l'angiotensine II
dans l'adaptation a une NSN. L'indométhacine a diminuC Ic debit
sanguin renal (RBF) chez NSN (—8,6%, P < 0,01) mais non chez les
contrOles. Les resistances vasculaires rCnales (RVR) se sont ClevCes
chez NSN (+9, 6%, P < 0,01) mais ont diminuC chez les contrOles
(—5,6%, P <0,01). GFR a diminuC chez NSN (—22,3%, P < 0,0!) mais
a augmenté chez les contrô!es (+ 10,3%, P < 0,001). L'excrCtion
urinaire de PGE2 a diminué de facon marquee chez les NSN et les
contrOles. Lors d'un traitement associant l'indomCthacine et Ia
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saralasine, RBF s'est ClevCe chez NSN (+22,4%, P < 0,01) mais n'a
pas change chez les contrôles. RVR adiminué chez NSN (—21,5%, P <
0,01) mais est restC inchange chez les contrOles. GFR ne s'est pas
modiflC chez les NSN et les contrOles. Avec Ia saralasine seule, RBF
s'est élevC chez les NSN (+21,4%, P < 0,001) et chez les contrôles
(+ 14,4% P <0,001). RVR a diminud chez les NSN (—21,8%, P <0,001)
et les contrOles (—18,7%, P < 0,001). GFR s'est élevée (+ 12,3%, P <
0,05) chez NSN, mais n'a pas change chez les contrOles. L'excrétion
urinaire de POE2 s'est élevée chez les NSN par rapport aux contrOles,
et a baissé de facon marquee chez les NSN après perfusion
d'indomCthacine ou de saralasine. Ces résultats indiquent une augmen-
tation, peut-être intrarCnale, de I'action de l'angiotensine II chez NSN,
et apporte Ia preuve d'une augmentation de l'action des prostaglandines
vasodilatatnces, qui pourrait Ctre secondaire a l'accroissement de
l'effet de l'angiotensine II.
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An accelerated form of the autologous phase of nephrotoxic
serum nephritis (NSN) can be induced in rats by injection of
rabbit anti-glomerular basement membrane (anti-GBM) anti-
body in animals previously sensitized to rabbit IgG. The sever-
ity of the lesion can be controlled by varying the quantity of
anti-GBM antibody administered. In this model of acute prolif-
erative glomerulonephntis, the whole kidney GFR remains
normal in spite of histological evidence of glomerular inflam-
mation and capillary lumen obliteration. Maddox et al. [1] found
that the capillary ultrafiltration coefficient (Kf) decreased to less
than 50% of normal in NSN, even though the single nephron
glomerular filtration rate (SNGFR) was normal. These studies
demonstrated a rise in glomerular capillary pressure (gc) as a
part of the adaptation to the disease. The increased Pgc
(accompanied by a corresponding increase in transglomerular
hydraulic pressure gradient () offset the expected effect of
reduced Kf on SNGFR. Additional experiments have also
demonstrated that the rise in gc is confined to the kidney with
nephritis in a unilateral model of NSN and that neither systemic
arterial hypertension nor plasma volume expansion is required
for the development of elevated Pgc in NSN [2J.
The purpose of these experiments was to explore the possible
roles of prostaglandins and angioten sin II (A-I!) in the adaptive
hemodynamic changes accompanying autologous phase of
NSN using indomethacin (I) as an inhibitor of prostaglandin
synthesis and saralasin (S) as a competitive inhibitor of A-I!
action.
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Methods
Preparation and characterization of the heterologous anti-rat
glomerular basement membrane antibody (anti-GBM Ab)
New Zealand white rabbits were repeatedly immunized with
ultrasonicated, insoluble rat glomerular basement membrane
(GBM) incorporated in complete Freund's adjuvant (CFA) as
described previously [1]. Rabbit IgG (RaIgG) was isolated from
normal, non-immune, and immune rabbit sera by DEAE cellu-
lose chromatography. Anti-GBM Ab content of the immune
IgG was determined by a paired-label method described previ-
ously [2, 3].
Induction of NSN in rats
NSN rats. Male Sprague-Dawley rats weighing 150 to 220 g
were preimmunized once in each rear footpad with 2.0 mg of
normal rabbit gammaglobulin (Cohn Fraction II, Miles Labora-
tory Research Products, Elkhart, Indiana, USA) incorporated
in 0.5 ml of CFA (9 ml of Baylol F, 1 ml Arlacel 83, and 6 mg
Mycobacterium Tuberculosis, H37Ra, Difco Laboratories, De-
troit, Michigan, USA). Two days later, the rats were infused via
a tail vein with immune RaIgG calculated to contain approxi-
mately 50 to 100 g of kidney-fixing antibody (KFAb).
Control rats. Normal Sprague-Dawley rats of the same body
weight as in NSN were preimmunized in the rear footpads with
normal rabbit gammaglobulin as described above, but instead of
receiving anti-GBM Ab were given a comparable amount of
non-immune RaIgG intravenously. After the infusion of anti-
GBM Ab, the rats were permitted free access to water and
standard rat chow until the time of hemodynamic study. Twen-
ty-four-hr urinary protein excretion was measured by
Kingsbury-Clark method [41 9 days after infusion of RaIgG.
Hemodynamic measurements
Hemodynamic studies were performed 10 to 14 days after
antibody injection. Rats weighing 236 to 337 g were divided into
3 groups. Group 1 received indomethacin infusion alone. Group
2 received combined indomethacin and saralasin. Group 3
received saralasin alone. Details of the infusions are given
below. Each group was divided into two subgroups: RBF was
measured in Subgroup A and GFR was measured in Subgroup
B.
Renal blood flow measurement (Groups JA, 2A, 3A)
Rats were anesthetized with mactin (100 mg/kg i.p.), placed
on a temperature-regulated table that maintained body temper-
ature at 37°C. After tracheostomy, the right femoral artery and
vein were catheterized with PE-50 polyethylene tubing. The
bladder was catheterized with PE-90 polyethylene tubing. A left
flank incision was made and left kidney was placed in a Lucite®
cup. The surface of the kidney was covered with Saran® wrap.
To maintain the euvolemic state, homologous rat serum was
infused for 30 mm during the surgical procedure into right
femoral vein; 0.36 ml for the NSN rat and 1.43 ml for control
rats, respectively. Each amount of serum was determined
empirically by the ability of the infusion to restore the systemic
hematocrit to baseline values during the surgical procedure [51.
Mean femoral arterial pressure (MAP) was monitored by means
of a strain-gauge transducer (Statham Instruments, Inc.,
Oxnard, California, USA) connected to a direct writing re-
corder. The left renal artery was gently freed from its surround-
ing connective tissue. Whole left kidney renal blood flow (RBF)
measurements were made by fitting the renal artery with an
electromagnetic flow transducer (Model EP 102, Carolina Med-
ical Electronic, Inc., King, North Carolina, USA (2.0 mm
circumference). The flow transducer was connected to an
electromagnetic flow meter (Pulsed-Logic, Model BL-610,
Biotronex Lab., Inc., Kensington, Maryland, USA). Calibra-
tion of the flow meter was done in vitro by pumping heparinized
blood from donor rats at known rates through an excised piece
of carotid artery. After the surgical preparations, the RBF and
MAP were allowed to stabilize for at least 20 mm before
commencing the experimental infusion. The vehicle was in-
fused for 20 mm, which was the same as the duration of the
experimental agent infusion. RBF measurement for baseline
values was performed for 5 mm in each experiment. Immedi-
ately thereafter, infusion studies were carried out for 20 mm
according to the protocol as described below, followed by
repeat measurement of RBF for 5 mm. Zero baseline for RBF
measurement was obtained by occluding the renal artery
distal to the flow transducer after completion of the flow
measurements.
Whole kidney glomerular filtration rate measurement (Groups
JB, 2B, 3B)
The rats were anesthetized and treated in the same manner as
the animals used in the blood flow measurements. The left
femoral vein was catheterized and an infusion of 10% inulin in
isotonic saline was given. A priming dose of approximately 0.4
ml was given over 10 mm and thereafter a constant infusion (1.2
mllhr) was maintained for 50 mm before measurements were
made. Urine samples from the bladder were collected with 1.0
ml of double distilled water in plastic tubes over 5-mm periods
at least 3 times after infusion of vehicle for 20 mm as the
control. Infusion studies of agents were carried out for 20 mm
according to the protocol as described below. Urine samples
were then collected with 1.0 ml of double distilled water in
plastic tubes. Urine flow rates were determined gravimetrically.
Arterial blood samples were obtained before and after each
period of urine collections. Inulin clearance values were calcu-
lated by standard formulae.
Infusion protocols
Group 1 (indomethacin infusion alone): Indomethacin (I) was
dissolved in a NaCI-Na2CO3 solution (0.88% NaC1 and 0.2%
Na2CO3) and infused in a priming dose of 2 mg/kg (0.5 ml) over
10 mm and in a maintenance dose of 2 mg/kg/hr (0.5 ml/hr) for
the remainder of the experiment. In each animal, a priming
infusion of 0.5 ml of vehicle given over 10 mm was followed by
an infusion of the vehicle described above at a rate of 0.5 mllhr
over 10 mi RBF and GFR measurements were performed as
controls. Immediately after the control measurement, the infu-
sion study of indomethacin was performed.
Group 2 (combined indomethacin (I) and saralasin (S)): The
competitive A-I! receptor blocker, saralasin (Sarcosine- 1, Ala-
nine-8, Angiotensin II, Beckman Instruments, Palo Alto, Cali-
fornia, USA), dissolved in 0.9% NaCl was infused at a rate of 5
sg/kg/min with indomethacin solution as described above
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Table 1. Renal blood flow (RBF), mean arterial pressure (MAP), and renal vascular resistance (RVR) in nephrotoxic serum nephritis (NSN)
and control rats before and after infusion of indomethacin, saralasin, or both
RVR
RBF mm Hg!
BW WKW
Unnary
protein Histological
mI/minig
kidney WI
mi/minlg
kidney WI
MAP
mm Hg
HCT
%
Group Condition (N) g g mg/24 hr score Before After Before After Before After Before After
Group IA, NSN (10) 275 2.13 8.3 2.6 9.29 8.49 11.35 12.43 99 101 42.1 446
indomethacin 5.5 0.06 1,9 0.3 0.53 0.53 0.84 1.07 I 3 0.7 0.7
alone
Control (10)
NS
270
NS
2.28
P < 0.01
2.8
P < 0.005
0.4
P < 0.001
7.83 8.13
P < 0.01
14.52 13.70
1.04
NS
108 106
P < 0.001
41.0 42.7
±0.3
NS P < 0.05 NS P < 0.00!
Group 2A, NSN (8) 272 2.14 5.8 1.4 5.85 7.16 18.48 14.50 105 99 44.6 44.8
indomethacin 6.5 0.06 0.9 0.4 0.32 0.50 1.30 1.30 2.4 1.8 0.9 0.8
plus saralasin
Control (8)
NS
275
11.2
NS
2.29
P < 0.001
1.2
NS
0,8
P < 0.001
6.44 6.59
P < 0.001
17.26 16.59
1.07
P < 0,001
109 109
NS
43.6 44.6
NS NS NS P<0.Ol
Group 3A, NSN (8) 273 2.10 5.5 2.2 7.45 9.05 14.36 11.23 104 99 46.3 46.5
saralasin 5.9 0.05 0.7 0.2 0.50 0.55 0.96 0.78 1 1 0.3 0.4
alone
Control (8)
NS
262
NS
2.26
P < 0.001
1.2
P < 0.05
0.8
P < 0.001
7.59 8.68
P < 0.001
14.58 11.85
1.08 1.03
P < 0.001
107 99
NS
47.8 48.0
±0.6
P < 0.001 P < 0.001 P < 0.001 NS
Values are shown as means I SE. Significance of differences of BW, WKW, urinary protein, and histological score in means between control
and NSN rats determined from unpaired data by Student's t test. Significance of differences between before and after RBF, RVR, MAP, and HCT
determined from paired data by Student's (test. Abbreviations are: BW, body weight; WKW, whole kidney weight; RBF, renal blood flow; RVR,
renal vascular resistance; MAP, mean arterial pressure; HCt, hematocrit; NS, not significant.
simultaneously for 20 mm and the measurements were started,
after control data were taken as described above.
Group 3 (saralasin (S) infusion alone): Saralasin dissolved in
0.9% NaCI was infused alone at a rate of 5 xglkglmin for 20 mm,
and the measurements were started after baselines were taken.
In this group, 0.9% NaCI was infused as vehicle for control.
This dose of S completely blocked the pressor response to an
acute intravenous bolus injection of angiotensin II sufficient in
untreated controls to raise the mean systemic arterial pressure
by at least 25 mm Hg.
Urina,y PGE2
Urinary PGE2 measurement on timed urine collections was
carried out by radioimmunoassay as described previously [6].
Pathological observations
After the experiments, both kidney weights were measured,
and a mid-coronal section of the right kidneys was fixed in 10%
neutral buffered formalin and sections were cut at 4 to 6 p after
embedding in parafin. Hematoxylin- and eosin-stained sections
were evaluted by one of us (RG) after slides were coded and
randomized. The severity of acute proliferative glomerular
lesions were graded 0 to 4+ on a semiquantitative scale as
described previously [I]. Selected samples were also studied by
direct immunofluorescence for deposition of rabbit and rat IgG.
Data analysis
Renal vascular resistance (RVR) was calculated from the
arterial pressure and renal blood flow per gram kidney wt. For
analysis of significance, the paired and unpaired t tests were
employed. For comparisons of the histological changes the
chi-square test was used. P values greater than 0.05 were
considered to be not statistically significant (NS).
Results
Pathology
Grossly, the kidneys were of normal size and color. Light
microscopic examination revealed relatively uniform changes
throughout the cortex. The glomerular lesions consisted prin-
cipally of mild to moderate proliferation of mesangial and/or
endothelial cells with segmental obliteration of capillary
lumens. Infiltration with monocytes and/or polymorphonuclear
leucocytes was also observed. Crescent formation and segmen-
tal necrosis were very rare. Interstitial changes were infrequent
and vascular changes were not seen. The results of semiquan-
titative analysis of histology is shown in Table 1 and 2. There
were significant differences of histological changes between
NSN and controls except in Group 2A. The immunofluorescent
studies revealed the expected linear deposits of rabbit IgG and
segmental or linear capillary wall deposits of rat IgG.
Proteinuria
The 24-hr urinary protein excretion in NSN was significantly
higher than controls in all groups (Table I and 2), although these
levels were not greatly elevated when compared to controls
(mean values were less than 10 mg/day).
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Measurement of RBF and RVR (Groups IA, 2A, 3A)
As shown in Table 1, before infusion of I and/or S no
significant differences of body wt, whole kidney wt, RBF, RVR,
MAP, and hematocrit were noted between NSN and control
rats except MAP in Group 1A. In Group A with 1 infusion
alone, RBF decreased from 9.29 0.53 to 8.49 0.53 mllminlg
kidney wt in NSN (— 8.6%, P < 0.001), but remained un-
changed in controls. The change in RBF between NSN and
controls is significant (P <0.001). The changes of RBF from the
baseline in individual experiments is shown in Figure 1. As can
be seen, a consistent and a significant reduction of RBF from
the baseline was observed in NSN, in contrast to no consistent
change in control rats. RVR increased by 9.6% in NSN (P <
0.01) and was slightly decreased by 5.6% in controls (P <0.05).
The changes in RVR between NSN and controls was significant
(P < 0.01).
In Group 2A with combined I and S infusion, a significant
increase of RBF (+ 22.4%, P < 0.001) was seen in NSN, but no
changes were observed in controls. The change in RBF be-
tween the two groups was significant (P < 0.05). RVR de-
creased 2 1.5% (P < 0.001) in NSN, but remained unchanged in
control rats. The change in RVR between NSN and controls
was also significant (P < 0.02).
In Group 3A with S infusion alone, RBF increased both in
NSN (+ 21.4%, P < 0.001) and in controls (+ 14.4%, P <
0.001). The change in RBF between the two groups was not
significant. Each change of RBF from baseline was very con-
sistent both in NSN and controls (Fig. 2). RVR decreased
markedly both in NSN (— 21.8%, P < 0.001) and controls
NSN Control
Fig. I. Changes in renal blood flow (RBF) from baseline following
indomethacin perfusion in rats with nephrotoxic serum nephritis (NSN)
and in control rats. ( , individual rats; , mean values SEM).
(— 18.7%, P < 0.001). The changes in RVR between the two
groups was not significant. The changes of RBF and RVR seen
in Group 3A were similar in direction to those observed in
Group 2A.
Table 2. Glomerular filtration rate (GFR), mean arterial pressure (MAP), and urinary PGE2 excretion in nephrotoxic serum nephritis (NSN)
and control rats before and after indomethacin, saralasin, or both
Group Condition (N)
GFR
NSN (8) 290
8.9
P < 0.02
Control (8) 263
4.7
Group IB,
indomethacin
alone
Group 2B,
indomethacin
plus saralasin
Group 3B,
saralasin
alone
Urinary
POE2
BW WKW
.
Urinary
protein Histological
mi/minig
kidney wt
MAP
mm HG
HCT
%
excretion
pg/mm
g g mg/24 hr score Before After
1.21 0.94
Before After
108 104
Before After
42.5 43.0
Before After
585 1512.33 5.5 2.4
0.06 0.8 0.2 0.10 0.11 5 5 0.8 0.9 176 13
P < 0.05 P < 0.01 P < 0.005 P < 0.01 P < 0.05 NS P < 0.05
2.13 2.8 0.3 1.30 1.45 108 105 42.5 43.0 445 159
0.06 0.4 0.2 0.06 0.07 3 3 0.8 0.9 70 15
P < 0.05 P < 0.02 NS P < 0.01
2.18 6.4 2.2 1.34 1.37 112 109 44.2 44.9 No Data
0.05 1.1 0.2 0.06 0.06 3 3 1.0 1.0
NS P < 0.001 P < 0.005 NS NS NS
2.13 0.5 0.8 1.24 1.29 110 108 46.8 47.5 No Data
0.06 0.1 0.1 0.05 0.06 3 3 0.8 0.8
NS NS NS
2.00 6.1 2.4 1.14 1.28 112 104 45.7 46.4 1261 335
0.06 1.0 0.3 0.10 0.09 3 3 0.7 0.7 273 52
P < 0,05 P < 0.001 P < 0.005 P < 0.05 P < 0.01 P < 0.05 P < 0.02
2.20 1.5 0.5 1.02 0.98 112 105 48.6 49.2 237 79
4.1 0.06 0.4 0.1 0.04 0.05 2 2 0.6 0.6 38 46
NSN (8) 284
7.9
NS
Control (8) 267
3.4
NSN (8) 253
5.3
P < 0.02
Control (10) 271
NS P<0.01
Values are shown as means I SE. Significance of differences in BW, WKW, urinary protein, and histological score between control and NSN
rats determined from unpaired data by Student's t test. Significance of differences between before and after GFR, MAP, HCT, and U PGE2
determined from paired data by Student's t test. Abbreviations same as Table 1.
NS P<0.0l
P < 0.001 NS
+1.5 —
+1.0 —
+0.5 —
0—
a
a
P
+1.5 —
+1.0 —
+0.5 —
0—
—0.5 —
—1.0 —
—1.5 —
—2.0 —
—0.5 —
—1.0—
—1.5—
—2.0 —
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combined I and S infusion in NSN prevented the decreased
GFR caused by I alone and prevented the increased GFR
caused by I in controls. In Group 3B, S infusion alone in NSN
P < 0.05 increased GFR (+ 12.3%, P < 0.05) but did not produce any
change in controls. The change in GFR between the two groups
was significant (P < 0.02). Seven of 8 animals showed increase
of GFR in NSN (Fig. 4). A summary of the renal hemodynamic
changes in NSN after I and/or S infusion is shown in Figure 5.
Urinary PGE2 excretion
As can be seen in Table 2, I infusion alone reduced urinary
PGE2 excretion both in NSN (P < 0.05) and in controls (P <
0.01). In addition, S infusion alone also reduced urinary PGE2
excretion in NSN (P < 0.02) and in controls (P < 0.01). A
significant increase in urinary PGE2 excretion was noted in
NSN compared to controls when data from Group lB and
Group 3B before infusion of I or S (Fig. 6) were pooled. Urinary
PGE2 excretion after I or S was also increased in NSN
compared to controls.
Discussion
The purpose of this study was to examine the participation of
the prostaglandin and angiotensin II systems in the adaptation
to the autologous phase of NSN by using indomethacin and
saralasin as pharmacologic inhibitors of these two systems,
respectively. Indomethacin resulted in a reduction in RBF and
GFR and a rise in RVR in NSN, whereas GFR was slightly
increased and RVR fell in controls. Saralasin resulted in rever-
sal of these abnormalities when infused with indomethacin in
NSN, and an increase in GFR was noted in NSN when saralasin
was infused alone. These hemodynamic changes are consistent
with increased action of vasodilator prostaglandins opposing
the action of an activated angiotensin II system.
We have previously argued that a part of the hemodynamic
adaptation to moderate autologous NSN is dilation of the
afferent arteriole and maintenance of tone or constriction of the
efferent arteriole, the combination being necessary to explain
the elevated Pgc and relatively unchanged or increased glomer-
ular plasma flow [2]. The consensus is that angiotensin II acts
on the efferent arteriole and mesangium [7—9]. The present
+4.0 —
P< 0.001
+3.0 —
+2.0 —
+1.0 —
P < 0.001
+4.0
+3.0
+2.0
:•:
NSN Control
Fig. 2. Changes in renal blood flow (RBF) from baseline following
saralasin infusion in rats with nephrotoxic serum nephritis (NSN) and
in control rats. Symbols same as Fig. I.
0—
P<0.05 NS
+0.4 +0.4
C
+0.2 +0.2
0 0 ___
J i:
Control
Fig. 4. Changes in glomerular filtration rate (GFR) from baseline
following saralasin infusion in rats with nephrotoxic serum nephritis
(NSN) and in control rats. Symbols same as Fig. 1.
NSN
P < 0.01
+0.6 —
+0.4 —
+0.2 —
0—
—0.2 —
—0.4—
—0.6—
—0.8 —
+0.6 —
+0.4 —
+0.2 —
0—
—0.2
— 0.4
—0.6
—0.8
C
a)
II
P
NSN Control
Fig. 3. Changes in glomerular filtration rate (GFR) from baseline
following indomethacin infusion in rats with nephrotoxic serum
nephritis (NSN) and in control rats. Symbols same as Fig. 1.
Measurement of GFR (Groups JB, 2B, 3B)
The values of GFR, MAP, and HCT before infusion were not
different between NSN and controls. Body wt and kidney wt
were slightly higher in NSN than controls in Group 1B, and
slightly lower in Group 3B. In Group lB, after infusion of I,
GFR decreased in NSN (— 22.3%, P < 0.01), but increased in
controls (+ 10.3%, P < 0.05). The changes in GFR between
groups was significant (P < 0.001). In NSN, all animals showed
consistent and significant decreases of GFR from baseline
following I infusion, in contrast to a slight increase of GFR in
control rats following I infusion alone (Fig. 3). In Group 2B, the
finding of enhanced sensitivity to angiotensin II inhibition in
NSN, together with the earlier findings, suggest that a cause of
the maintenance of tone or increased efferent arteriolar resist-
ance in NSN is the increased action of angiotensin II. Rats with
NSN are known to be normotensive and volume expanded [21,
circumstances which should be associated with low plasma
renin activity. These results may therefore point to an enhanced
intrarenal action of angiotensin II in NSN, either from in-
creased local release of renin, from increased local conversion
of angiotensin Ito angiotensin H, or from increased sensitivity
to angiotensin II due to changes in receptor affinity or density or
to post-receptor events.
Although we have interpreted our data to indicate an in-
creased intrarenal action of angiotensin II, care should be
exercised in extrapolating this conclusion to conscious animals
or to human patients. The anesthesia our studies required can
activate renin secretion, and conscious animals might be less
sensitive to saralasin or indomethacin than anesthetized ones.
This caveat applies to all studies of renal function conducted
with micropuncture techniques.
The glomerulus can produce prostaglandins such as PGI2,
TxA2, PGF2a, and PGE2 [10—13]; A-lI is a potent stimulator of
POE2 production [14, 15]; and PGE2 attenuates the vasocon-
strictor action of angiotensin II [16, 171. A single hypothesis
that unifies our findings in NSN with these statements is that the
maintenance of tone or vasoconstriction of the efferent arteriole
that is a part of the adaptation to the disease [2] is mediated by
angiotensin II and modulated by POE2. The finding in this study
that saralasin reduces urinary PGE2 excretion in NSN is
consistent with this hypothesis because it implies that the
increase is due primarily to an angiotensin Il-provoked process.
The urinary PGE2 excretion data are no more than consistent,
however, because there is no direct evidence that prostaglan-
dins produced in the cortex of the kidney are excreted into the
urine in quantitatively significant amounts, and, even if they
are, the relationship between production of prostaglandins at
the site and urinary excretion need not be linear.
Blantz et at [181 failed to find preventive effects of saralasin
on immune-induced vasoconstriction or the reduction of Kf in
the acute heterologous phase of NSN, whereas our experimen-
tal model was studied in the autologous phase. The heterolo-
gous phase occurring within minutes to hours after injection of
immune rabbit IgG is known to involve complement activation,
with subsequent emigration of polymorphonuclear cells and
enzymatic-induced damage to the glomerular capillary wall
[19]. But the autologous phase, which develops when the host's
immune system reacts to the glomerular-bound heterologous
anti-GBM antibody, predominantly involves monocytes/macro-
phages as inflammatory mediators [20]. The vasoconstriction
seen in the heterologous model should be contrasted with the
hemodynamic alterations vasodilitation observed in the autolo-
gous model [1, 2]. Lianos et al and Scharschmidt et al [16, 21]
also used the heterologous model and showed that increased
thromboxane A2 production occurred in isolated glomeruli from
NSN and that thromboxane A2 might be responsible for some of
the vasoconstriction observed in the heterologous model. It is,
however, still unknown which vasodilator prostaglandins are
produced in the autologous phase of NSN and play an impor-
tant role in adaptation.
NSN produces a glomerular lesion that is reflected in a
reduction of the glomerular capillary ultrafiltration coefficient
(Kf or LpA). GFR is maintained at normal levels by virtue of an
elevation ofgc [1, 2]. The elevation in gc is constructed from
a combination of maintenance of tone or constriction of the
efferent arteriole and dilatation of afferent arteriole. The find-
ings presented here and earlier [2] identify some of the causality
in the adaptive response, and probably provide a sufficient
explanation of events in the efferent arteriole. The cause of the
afferent artiolar dilatation remains unexplained. One possibility
is that the disease process itself directly stimulates production
of vasodilator prostaglandins. Although we have not tested this
hypothesis rigorously, we regard it as unlikely. The effects of
indomethacin can be pre-empted by saralasin, suggesting that
the changes in prostaglandin effects in NSN are due chiefly to
angiotensin II stimulation, and angiotensin II is not a vasodila-
tor. In our opinion, the cause of the afferent dilatation must be
sought in other processes. The effects of indomethacin to
reduce GFR in mild glomerular disease in humans could be
counterpart of the effects observed in present study [22].
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Fig. 5. Summary of changes from baseline of renal
blood flow (RBF), renal vascular resistance (RVR),
and glomerular filtration rate (GFR) for experiments
involving indomethacin infusion alone (I); combined
indomethacin and saralasin infusion (1 + 5); and
saralasin infusion alone (5). Absolute changes fromP< 0.001 NS baseline shown as mean SEM.
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Fig. 6. Urinary PGE2 excretion (U-PGE2) in rats with nephrotoxic
serum nephritis (NSN) compared to control rats prior to infusion of
indomethacin and/or saralasin. Values given as mean SEM.
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